BioCentury | Feb 18, 2020
Finance

Feb. 18 Financial Quick Takes: Imara's IPO filing, Passage's terms, and fundings for OMass and Univercells

Imara listing would bring liquidity to NEA-led group  Hematology company Imara Inc. filed to raise up to $86.3 million in an IPO on NASDAQ. The company's prospectus said New Enterprise Associates is its largest shareholder...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

Former FDA Commissioner Scott Gottlieb joined the board of next-generation sequencing company Illumina Inc. (NASDAQ:ILMN). The new role is at least his fourth board appointment since stepping down from the agency last year. Along with...
BioCentury | Feb 5, 2020
Politics, Policy & Law

Trump boosts Grassley-Wyden drug pricing bill

President Donald Trump and Vice President Mike Pence have publicly endorsed pending Senate legislation that seeks to restructure the Medicare Part D drug benefit and impose inflation caps on prescription drug prices. “I’ve been speaking...
BC Extra | Feb 1, 2020
Financial News

Arcutis gains in this year’s third biotherapeutic IPO on NASDAQ

The aftermarket performance of two IPOs in January’s final week suggests investors’ appetite for new biotech listings remains robust. In NASDAQ’s third biotherapeutic IPO of the year, dermatology company Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) raised $159.4...
BC Extra | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

Black Diamond raises $201M in public debut  Black Diamond Therapeutics Inc. (NASDAQ:BDTX) raised $201.1 million late Wednesday through the sale of 10.6 million shares at $19 in a bumped-up IPO, valuing the company at $652.1...
BioCentury | Jan 25, 2020
Product Development

The race is on to develop therapies and vaccines for the coronavirus outbreak

Public release of the genetic sequence of the coronavirus first detected in Wuhan, China acted as a starter pistol, setting off a race to develop medical countermeasures. Beyond the potential for containing and hopefully eradicating...
BC Extra | Jan 3, 2020
Financial News

Jan. 3 Financial Quick Takes: Black Diamond plots IPO; plus Oxford Nanopore, CF PharmTech, Mygene and Zerun

Black Diamond seeking NASDAQ listing  Tumor-agnostic precision oncology company Black Diamond Therapeutics Inc. filed for an IPO on NASDAQ worth up to $100 million. Shepherded since 2017 by lead investor Versant Ventures, the company is...
BC Extra | Dec 20, 2019
Politics & Policy

Hahn signals new messaging style as he commandeers FDA Twitter account, vaporizes Gottlieb

Stephen Hahn’s tenure as FDA commissioner has begun with a personal dispute with his predecessor over control of a Twitter account. Sworn in as commissioner on Tuesday, Hahn now has possession of an account previously...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors. Strategies to convert immunosuppressive macrophage...
BC Extra | Dec 5, 2019
Financial News

Black Diamond raises $85M series C, shoots to enter clinic next half

As Black Diamond prepares to bring its first cancer candidate to the clinic and build out its tumor-agnostic pipeline, the company has raised $85 million in a oversubscribed series C led by new investor Boxer...
Items per page:
1 - 10 of 698
BioCentury | Feb 18, 2020
Finance

Feb. 18 Financial Quick Takes: Imara's IPO filing, Passage's terms, and fundings for OMass and Univercells

Imara listing would bring liquidity to NEA-led group  Hematology company Imara Inc. filed to raise up to $86.3 million in an IPO on NASDAQ. The company's prospectus said New Enterprise Associates is its largest shareholder...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

Former FDA Commissioner Scott Gottlieb joined the board of next-generation sequencing company Illumina Inc. (NASDAQ:ILMN). The new role is at least his fourth board appointment since stepping down from the agency last year. Along with...
BioCentury | Feb 5, 2020
Politics, Policy & Law

Trump boosts Grassley-Wyden drug pricing bill

President Donald Trump and Vice President Mike Pence have publicly endorsed pending Senate legislation that seeks to restructure the Medicare Part D drug benefit and impose inflation caps on prescription drug prices. “I’ve been speaking...
BC Extra | Feb 1, 2020
Financial News

Arcutis gains in this year’s third biotherapeutic IPO on NASDAQ

The aftermarket performance of two IPOs in January’s final week suggests investors’ appetite for new biotech listings remains robust. In NASDAQ’s third biotherapeutic IPO of the year, dermatology company Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) raised $159.4...
BC Extra | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

Black Diamond raises $201M in public debut  Black Diamond Therapeutics Inc. (NASDAQ:BDTX) raised $201.1 million late Wednesday through the sale of 10.6 million shares at $19 in a bumped-up IPO, valuing the company at $652.1...
BioCentury | Jan 25, 2020
Product Development

The race is on to develop therapies and vaccines for the coronavirus outbreak

Public release of the genetic sequence of the coronavirus first detected in Wuhan, China acted as a starter pistol, setting off a race to develop medical countermeasures. Beyond the potential for containing and hopefully eradicating...
BC Extra | Jan 3, 2020
Financial News

Jan. 3 Financial Quick Takes: Black Diamond plots IPO; plus Oxford Nanopore, CF PharmTech, Mygene and Zerun

Black Diamond seeking NASDAQ listing  Tumor-agnostic precision oncology company Black Diamond Therapeutics Inc. filed for an IPO on NASDAQ worth up to $100 million. Shepherded since 2017 by lead investor Versant Ventures, the company is...
BC Extra | Dec 20, 2019
Politics & Policy

Hahn signals new messaging style as he commandeers FDA Twitter account, vaporizes Gottlieb

Stephen Hahn’s tenure as FDA commissioner has begun with a personal dispute with his predecessor over control of a Twitter account. Sworn in as commissioner on Tuesday, Hahn now has possession of an account previously...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors. Strategies to convert immunosuppressive macrophage...
BC Extra | Dec 5, 2019
Financial News

Black Diamond raises $85M series C, shoots to enter clinic next half

As Black Diamond prepares to bring its first cancer candidate to the clinic and build out its tumor-agnostic pipeline, the company has raised $85 million in a oversubscribed series C led by new investor Boxer...
Items per page:
1 - 10 of 698